Study	Patients with schizophrenia			Healthy controls			Standardised Mean Difference	SMD	95%-CI	Weight (fixed)	Weight (random)
	Total	Mean	SD	Total	Mean	SD					
metabolite = Glu											
da Silva Alves et al. 2011 (45)	11	6.39	1.3200	23	6.44	1.3500		−0.04	[−0.76; 0.68]	4.0%	5.9%
Goldstein et al. 2015 (41)	42	1.17	0.0766	15	1.12	0.0500		0.68	[0.07; 1.28]	5.8%	7.1%
Hugdahl et al. 2015 (40)	18	5.60	3.0000	26	7.63	2.9025		−0.69	[−1.31; −0.07]	5.5%	6.9%
Smesny et al. 2015 (49)	31	11.61	1.0800	31	10.49	1.6840		0.79	[0.28; 1.31]	7.8%	8.2%
Chen et al. 2017 (39)	24	1.64	2.1514	24	1.28	1.8677		0.18	[−0.39; 0.75]	6.5%	7.5%
Maddock et al. 2018 (47)	17	0.90	0.0700	25	0.90	0.0800		0.00	[−0.62; 0.62]	5.5%	7.0%
Iwata et al. 2019 (38)	64	14.02	1.5500	26	13.94	1.3200		0.05	[−0.40; 0.51]	10.1%	9.0%
Kaminski et al. 2019 (25)	55	7.92	1.0900	35	8.22	0.9000		−0.29	[−0.72; 0.13]	11.5%	9.4%
Wang et al. 2019 (46)	72	6.41	0.7500	84	6.65	0.5200		−0.38	[−0.69; −0.06]	20.7%	10.9%
Fixed effect model	**334**			**289**				−0.04	[−0.21; 0.12]	77.4%	−−
Random effects model								0.02	[−0.28; 0.33]	−−	71.9%
Heterogeneity: $I^2 = 68\%$, $\tau^2 = 0.1431$, $p < 0.01$											
metabolite = Glx											
Goto et al. 2012 (48)	18	0.79	0.2800	18	0.67	0.4000		0.35	[−0.31; 1.01]	4.8%	6.5%
Kegeles et al. 2012 (74)	32	0.00	0.0011	22	0.00	0.0005		−0.27	[−0.82; 0.27]	7.0%	7.8%
Jessen et al. 2013 (43)	20	2.11	0.3000	20	2.06	0.3300		0.16	[−0.46; 0.78]	5.4%	6.9%
Coughlin et al. 2015 (42)	25	1.40	0.2300	16	1.37	0.2060		0.12	[−0.51; 0.75]	5.3%	6.8%
Fixed effect model	**95**			**76**				0.05	[−0.25; 0.36]	22.6%	−−
Random effects model								0.05	[−0.25; 0.36]	−−	28.1%
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.53$											
Fixed effect model	**429**			**365**				**−0.02**	**[−0.16; 0.12]**	**100.0%**	**−−**
Random effects model								**0.03**	**[−0.20; 0.26]**	**−−**	**100.0%**
Heterogeneity: $I^2 = 58\%$, $\tau^2 = 0.1009$, $p < 0.01$											
Residual heterogeneity: $I^2 = 60\%$, $p < 0.01$											